Phase 1/2Completed
Gene Therapy for APOE4 Homozygote of Alzheimer's Disease
A 52-Week, Multicenter, Phase 1/2 Open-label Study to Evaluate the Safety of LX1001 in Participants With APOE4 Homozygote Alzheimer's Disease
- Sponsor
- Lexeo Therapeutics (Industry)
- Enrolment
- 15 enrolled
- Conditions
- Alzheimer Disease; Early Onset Alzheimer Disease
- Interventions
- LX1001
- Ages
- adults, older adults
- Registry
- NCT03634007
From the registry
This clinical trial is an open label, dose-ranging study designed to evaluate gene therapy to treat patients who are APOE4 homozygotes with clinical diagnosis varying from mild cognitive impairment due to Alzheimer's, mild dementia due to Alzheimer's disease, and moderate dementia due to Alzheimer's disease.
Primary outcomes
- Proportion of participants with treatment-emergent adverse events and serious adverse events
- The proportion of participants with treatment-emergent adverse events and serious adverse events at each dosage